NCT04743193

Brief Summary

After reaching 1 MAC level with 4 lt / min fresh gas flow and 2.5% sevoflurane concentration in the initial stage in 35 patients, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC. For 35 patients, after reaching 1 (MAC) level with 1 lt / min fresh gas flow and 8% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration, targeting 1 MAC.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 2, 2021

Completed
3 days until next milestone

Study Start

First participant enrolled

February 5, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 8, 2021

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 28, 2021

Completed
17 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 15, 2021

Completed
Last Updated

September 1, 2021

Status Verified

August 1, 2021

Enrollment Period

3 months

First QC Date

February 2, 2021

Last Update Submit

August 27, 2021

Conditions

Keywords

inhalation

Outcome Measures

Primary Outcomes (1)

  • sevoflurane versus desflurane

    To compare the instant and total consumption of sevoflurane using 2 different concentrations and different minute / fresh gas flow to fill the system in the initial phase of anesthesia.

    the study will comlete in one month

Secondary Outcomes (1)

  • sevoflurane

    studdy will complete in one month

Study Arms (2)

sevoflurane 8 %

In the initial phase, after reaching 1 (MAK) level with 1lt / min fresh gas flow and 8% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.

Other: 8% sevoflurane low flow anesthesia

sevoflurane 2.5 %

In the initial phase, after reaching 1 MAK level with 4 lt / min fresh gas flow and 2.5% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.

Other: 2.5 %sevoflurane

Interventions

for 35 patients after reaching 1 MAK level with 4 lt / min fresh gas flow and 2,5% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 minimum alveolar concentration

sevoflurane 2.5 %

For 35 patients after reaching 1 (MAC) level with 1 lt / min fresh gas flow and 8% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration, targeting 1 MAC. .

sevoflurane 8 %

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

* Patients between the ages of 18-65 * ASA1,2,3 group patients

You may qualify if:

  • Patients between the ages of 18-65
  • ASA1,2,3 group patients
  • Patients under general anesthesia
  • Patients scheduled for elective surgery

You may not qualify if:

  • The patient's refusal to participate in the study
  • Patients with less than 90 minutes of total anesthesia time
  • Patients whose total anesthesia time exceeds 180 minutes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tahsin Şimşek

Istanbul, Kartal, 34000, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Respiratory Aspiration

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

February 2, 2021

First Posted

February 8, 2021

Study Start

February 5, 2021

Primary Completion

April 28, 2021

Study Completion

May 15, 2021

Last Updated

September 1, 2021

Record last verified: 2021-08

Locations